Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Washington University School of Medicine
Beijing Kejing Biotechnology Co., Ltd.
Roswell Park Cancer Institute
Mainline Biosciences, Inc.
M.D. Anderson Cancer Center
NKGen Biotech, Inc.
Southwest Hospital, China